Patients whose oral tongue cancer returns within three months of curative surgery face a sharply poorer long-term outlook than those who stay disease-free, according to a retrospective study of 944 people published in Clinical and Experimental Otorhinolaryngology and reported by the European Medical Journal. Five-year overall survival among patients with this rapid relapse was 46.1%, compared with 88.5% among those without early recurrence. The analysis covered patients with oral tongue squamous cell carcinoma who had undergone surgery intended to cure the disease.
Why it matters
The gap between the two survival figures is wide enough to make timing of relapse a major factor in how patients are monitored and treated. The authors describe rapid relapse as one of the strongest adverse prognostic signals in this group, and they argue that current follow-up schedules can leave the highest-risk patients unobserved during the period when recurrence is most likely. Their proposed answer is a scoring tool that flags those patients before treatment failure becomes visible on standard scans.
What drove early failure
The researchers used multivariable logistic regression to identify which clinical and metabolic features were associated with relapse inside three months.
Larger primary tumours carried the heaviest weight: stage T2 to T4 disease raised the odds of early relapse by close to six times. Extensive spread to regional lymph nodes, classified as N3, was linked to an odds ratio of 5.39. Margins that were microscopically positive after resection produced an odds ratio of 5.22. Perineural invasion on pathology doubled the odds of early failure.
Metabolic imaging added a further signal. The maximum standardised uptake value, or SUVmax, measured on a preoperative PET scan of the primary tumour acted as a continuous predictor, with each one-unit rise in tracer uptake associated with a 14% increase in risk.
A nomogram for triage
The team combined these variables into a predictive nomogram. It takes in tumour extent, nodal status, resection margin status, perineural invasion, PET metabolic values and the initial management approach.
Internal validation using cross-validation produced area under the curve values of 0.715 and 0.736, with what the investigators describe as strong calibration. In practical terms, the tool sorts patients into low-, intermediate- and high-risk tiers. Low-risk patients could stay on standard monitoring, while the higher tiers would move to more intensive surveillance.
Treatment and timing questions
Adjuvant concurrent chemoradiotherapy was associated with a notable protective effect in the analysis, cutting early failure by 66% and improving survival.
The authors also question when restaging should happen. Standard guidelines call for initial restaging imaging only several months after adjuvant treatment ends, which in their view leaves vulnerable patients unexamined during a critical window. They recommend baseline PET-CT restaging within four to six weeks of surgery for patients whose predicted probability of failure exceeds 50%.
The reasoning is that an early metabolic scan can reveal microscopic residual disease before it has grown substantially, giving clinicians room to adjust radiation fields, start systemic therapy sooner or move to salvage treatment.
Caveats and what to watch
The findings come from a single retrospective cohort, and the nomogram's performance figures derive from internal validation rather than testing in an independent group of patients. That distinction matters before the tool is adopted into routine practice, since prediction models often perform less well when applied to new populations.
The study appears in the 2026 volume of Clinical and Experimental Otorhinolaryngology. The next thing to watch is whether outside centres test the nomogram on their own patients and whether early post-surgical PET-CT restaging is evaluated prospectively against the conventional schedule.
